Amicus Therapeutics Inc
Most Recent
Company & Industry OverviewsHere Are Amicus’s Key Research Programs in 2019
Amicus Therapeutics is targeting a market opportunity worth more than $1.0 billion to $2.0 billion with its investigational AT-GAA ERT in the Pompe disease indication.
Company & Industry OverviewsHow Is Amicus Therapeutics’ Galafold Placed in the First Quarter?
According to the first-quarter earnings conference call, Amicus Therapeutics doesn’t expect linear revenue growth for Galafold on a quarter-over-quarter basis.
Company & Industry OverviewsFOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019
Analysts expect Amicus Therapeutics’ revenues to rise YoY by 89.66% to $173.05 million in fiscal 2019.
Company & Industry OverviewsWhat Are Analysts Recommending for FOLD and PTLA in May?
Amicus Therapeutics and Portola Pharmaceuticals both have a consensus “buy” rating in May.
Company & Industry OverviewsHow Are Sangamo Therapeutics’ Earnings and Expenses Trending?
In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.
Company & Industry OverviewsJazz Pharmaceuticals: Analysts’ View in November
On November 12, Jazz Pharmaceuticals’ stock price closed at $148.54, which represents ~2.04% growth from the close of $145.57 on November 9.
Company & Industry OverviewsLook at Acadia Pharmaceuticals Stock: It Rose 7.9% on Tuesday
On Tuesday, September 25, Acadia Pharmaceuticals (ACAD) stock closed at $21.41. That’s 7.86% higher than its prior day’s close of $19.85.
Company & Industry OverviewsAnalyzing PTC Therapeutics’ Performance in September
On September 13, PTC Therapeutics’ stock price closed at $47.33, which is ~0.66% growth from the close of $47.02 the previous day.
Company & Industry OverviewsAnalyzing Audentes Therapeutics’ Valuation Metrics
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.
Company & Industry OverviewsHow Analysts View Amicus Therapeutics in September
Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.
Company & Industry OverviewsWhy Amicus Therapeutics Stock Rose Last Week
Amicus Therapeutics (FOLD) saw a 19% rise in its stock in the week ended May 18.
Company & Industry OverviewsAnalyzing the Market Potential for Amicus’s Galafold
According to Amicus Therapeutics, the annual incidence of the disease in newborn males is estimated to be between 1:40,000 and 1:60,000.
Company & Industry OverviewsExploring Amicus Therapeutics’ Promising Research Pipeline
Amicus Therapeutics’ most recent novel proprietary enzyme replacement therapy is currently in late preclinical development.
Company & Industry OverviewsAnalysts Rate Voyager Therapeutics and Its Peers in April
Voyager Therapeutics is a clinical-stage gene therapy company with a focus on developing treatments for severe neurological diseases.
Company & Industry OverviewsWhy Amicus Therapeutics Stock Rose in the Week Ended March 29
On March 29, 2018, Amicus Therapeutics (FOLD) was trading at $15.04, which represented a ~135% rise from its 52-week low of $6.41.
Company & Industry OverviewsIBB Small-Caps Reduce Negative Returns in December
The small-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) rose 1.4% on December 21, 2015, and reduced the negative returns.